PTC Inc. logo PTC - PTC Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 20
HOLD 10
SELL 3
STRONG
SELL 0
| PRICE TARGET: $193.86 DETAILS
HIGH: $210.00
LOW: $180.00
MEDIAN: $195.00
CONSENSUS: $193.86
UPSIDE: 30.78%

Stock News

PTC's Codebeamer Powers Mazda's Software-Defined Vehicle Development

PTC's Codebeamer Powers Mazda's Software-Defined Vehicle Development

Mazda selects Codebeamer ALM solution to help strengthen requirements management, improve quality, support compliance, and accelerate innovation for software-defined vehicle development Maintains connectivity to Mazda's advanced Model-Based Development (MBD) Establishes foundation for integrated product development and future AI-enabled workflows BOSTON, May 21, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Mazda Motor Corporation, a leading global automaker, has selected the PTC Codebeamer® Application Lifecycle Management (ALM) solution to support its software-defined vehicle development (SDV). Mazda will use Codebeamer to standardize requirements, testing, and validation, enabling end-to-end traceability and faster product development while meeting automotive standards.

May 21, 2026 04:30 AM • prnewswire.com
PTC for Startups Program Helps Companies Design, Produce, and Launch Next-Generation Products

PTC for Startups Program Helps Companies Design, Produce, and Launch Next-Generation Products

Free access to Onshape, Creo+, Codebeamer+, and a startup package for Arena to manage every stage of the product lifecycle from design and development through compliance and launch Annual renewals available to support startups through key funding and revenue milestones Exposure to PTC's global ecosystem to support industry visibility BOSTON , May 13, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the expansion of its startup program to companies across all industries, extending a model that began with its Aerospace and Defense Startup Program, launched in 2025. Building on that program's success, PTC for Startups now makes PTC's professional-grade product development tools available to qualifying early and growth-stage startups worldwide — at no cost.

May 13, 2026 04:30 AM • prnewswire.com
PTC Onshape Introduces Direct Altium Integration to Streamline ECAD-MCAD Collaboration

PTC Onshape Introduces Direct Altium Integration to Streamline ECAD-MCAD Collaboration

Connects Printed Circuit Board (PCB) design from Altium directly into Onshape in a unified cloud-native workflow Eliminates file-based PCB data exchange between electrical and mechanical design Streamlines inclusion of detailed components in your personal or company library BOSTON, May 12, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced a new integration between its cloud-native Onshape® computer‑aided design (CAD) and product data management (PDM) platform and Altium. The connector enables electrical and mechanical engineering teams to collaborate more effectively by bringing Printed Circuit Board (PCB) designs directly into Onshape and keeping changes synchronized across both platforms.

May 12, 2026 04:30 AM • prnewswire.com
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.

May 09, 2026 07:21 PM • seekingalpha.com
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

May 07, 2026 12:01 PM • prnewswire.com
PTC ANNOUNCES SECOND FISCAL QUARTER 2026 RESULTS

PTC ANNOUNCES SECOND FISCAL QUARTER 2026 RESULTS

Strategic focus on Intelligent Product Lifecycle vision Solid execution in Q2'26 Constant currency ARR growth of 8.5% excluding divested businesses Operating and free cash flow growth of 14% ~$625 million of cash used for repurchases in Q2'26; targeting repurchases of ~$1.225 billion to ~$1.325 billion in FY'26; New $2 billion share repurchase authorization effective for FY'27-FY'28. BOSTON, May 6, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its second fiscal quarter ended March 31, 2026.

May 06, 2026 12:01 PM • prnewswire.com
PTC's Windchill PLM designated by U.S. Army as its Official Enterprise Product Data Management (ePDM) Solution

PTC's Windchill PLM designated by U.S. Army as its Official Enterprise Product Data Management (ePDM) Solution

Windchill enables enterprise-scale digital engineering from acquisition to sustainment Streamlines governance and supports modernization, increases availability of essential mission-critical data Allows for identification of cost-reduction opportunities BOSTON, May 6, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the U.S. Army has designated the Windchill® product lifecycle management (PLM) solution as its official Product Data Management (PDM) and Product Lifecycle Management (PLM) platform. The U.S. Army, through a DEVCOM‑led initiative, is advancing a modern PLM environment to improve the management, governance, and reuse of authoritative product data across the Army enterprise.

May 06, 2026 04:30 AM • prnewswire.com
PTC Codebeamer Replaces Legacy System at Hamilton Medical

PTC Codebeamer Replaces Legacy System at Hamilton Medical

Collaboration agreement formed to advance market-specific ALM-PLM solutions Codebeamer ALM solution selected to enhance collaboration, validation, traceability, and regulatory compliance across product development workflows Multi-year collaboration aims to advance PTC's ALM and PLM market-specific capabilities BOSTON, May 5, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Hamilton Medical, a global leader in intelligent mechanical ventilation solutions, selected PTC's Codebeamer® Application Lifecycle Management (ALM) solution to replace its legacy ALM system and paper-based processes. Further, PTC and Hamilton Medical, a long-term user of PTC's Windchill® Product Lifecycle Management (PLM) solution, have agreed to collaborate to strengthen mutual outcomes.

May 05, 2026 04:30 AM • prnewswire.com
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile -  - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET -  WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort.

Apr 28, 2026 12:05 PM • prnewswire.com

Price Targets